Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.72 |
| ▸ | DRD1 | P21728 | 5/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triflupromazine SCHEMBL5311245 | 0.92 | CYP2D6 (0.80) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| SCHEMBL26000537 | 0.87 | FPR2 (0.75) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| SCHEMBL2892321 | 0.86 | CYP2D6 (0.71) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| SCHEMBL2892325 | 0.86 | CYP2D6 (0.71) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| Triflupromazine SCHEMBL20610220 | 0.85 | CYP2D6 (0.71) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| Methylpromazine SCHEMBL18993 | 0.85 | CHRM2 (1.00) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| Methylpromazine SCHEMBL18994 | 0.85 | CHRM2 (1.00) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| Methylpromazine SCHEMBL29354434 | 0.85 | CHRM2 (1.00) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| Triflupromazine SCHEMBL13724400 | 0.85 | CYP2D6 (0.68) | HTR1AADRA2ACHRM1DRD1ADRA1A | |
| SCHEMBL13284571 | 0.84 | CHRM2 (0.78) | HTR1AADRA2ACHRM1DRD1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102935068-B | Preparation method of liposome entrapping water-soluble medicines | ZHEJIANG HISUN PHARM CO LTD | 2014-12-17 | — | — | CN | claimed |
| CN-102935068-A | Preparation method of liposome entrapping water-soluble medicines | ZHEJIANG HISUN PHARM CO LTD | 2013-02-20 | — | — | CN | claimed |
| CN-101426495-A | CB1 antagonists and inverse agonists | AMPLA PHARMACEUTICALS INC (US) | 2009-05-06 | — | — | CN | claimed |
| WO-2025093589-A1 | HETEROARYL AMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025093590-A1 | HETEROARYL ESTER DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023037254-A1 | METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | DIDENKO KIRILL (MX) | 2023-03-16 | — | — | WO | disclosed |
| US-10376522-B2 | Triarylmethane analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-20170000801-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | THE US GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2017-01-05 | — | — | US | disclosed |
| US-20170000801-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | THE US GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2017-01-05 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020040359-A1 | Method and apparatus for normalizing and converting structured content | ORACLE INTERNATIONAL CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20020040359-A1 | Method and apparatus for normalizing and converting structured content | ORACLE INTERNATIONAL CORPORATION | 2002-04-04 | — | — | US | disclosed |
| WO-2002001401-A1 | METHOD AND APPARATUS FOR NORMALIZING AND CONVERTING STRUCTURED CONTENT | ONEREALM INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002001401-A1 | METHOD AND APPARATUS FOR NORMALIZING AND CONVERTING STRUCTURED CONTENT | ONEREALM INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001096335-A1 | IMIDAZO[1,2-A]PYRIDINE ETHER COMPOUNDS AS ION CHANNEL MODULATORS | CARDIOME PHARMA CORP. (CA) | 2001-12-20 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000801-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | TK2, TXNRD2, TXN2 | HTR1A 3040/4885ADRA2A 2595/4885CHRM1 4646/4885 |
| US-10376522-B2 | Triarylmethane analogs and their use in treating cancers | TK2, TXNRD2, TXN2 | HTR1A 3045/4885ADRA2A 2553/4885CHRM1 4644/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | HTR1A 4030/4885ADRA2A 2412/4885CHRM1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.